POSC280 Economic Evaluation of Nivolumab Plus Ipilimumab in Advanced Renal-Cell Carcinoma in Japan

Abstract

Authors

T Maeda K Morimoto X Mo K Moriwaki K Shimozuma

Full Text Cite This Article
Back to ISPOR Europe 2021 Abstracts: Emerging Frontiers and Opportunities
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×